In other recent news, Humana has announced its Medicare Advantage and Medicare Prescription Drug Plan offerings for 2026, emphasizing that over 80% of its members will enjoy stable benefits. This comes as Wolfe Research raised its price target for Humana to $313 from $283, maintaining an Outperform rating, following the company's commentary on 2026 Medicare Advantage Star ratings. Meanwhile, Cantor Fitzgerald has maintained its Neutral rating with a $290 price target amid changes in Indiana's Medicaid enrollment, which include new restrictions and requirements. Raymond James reiterated an Outperform rating for Humana, with a price target of $340, despite challenges in the 2026 Stars Ratings cut points that could affect the company's ratings recovery. Additionally, a U.S. bankruptcy court has approved CenterWell Senior Primary Care's acquisition of The Villages Health assets, which is expected to close in the fourth quarter of 2025.